Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report

Frontiers in Endocrinology 2026 Open access

Read full text
Authors: Hanene Lassoued, Olivier Lamy, Cyril Francioli, Elena González Rodríguez
DOI: 10.3389/fendo.2026.1761311
Cited by: 1
References: 11

Abstract

Atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) are rare but serious complications associated with long-term use of antiresorptive therapies such as denosumab. Denosumab discontinuation to allow for bone healing is not possible because of the high risk of spontaneous multiple vertebral fractures. We present a case of concurrent AFF and ONJ in a patient previously treated with denosumab 120mg monthly. The patient was managed with a low-dose denosumab regimen tailored according to bone turnover marker monitoring, resulting in successful bone union and resolution of ONJ.

Fields of Study & Subjects

Bone health and treatments Bone and Joint Diseases Oral health in cancer treatment

Publication details

Journal / source
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Volume
17
Pages
1761311–1761311
Publication date
24 February 2026
Language
EN